Pancreatic Cancer Research

ResearcherUniversità Campus Bio-MedicoActive in the last 2 years

Daniela Pozzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6158-5880; OpenAlex author ID A5013516500. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 16

  1. Nanoparticle-protein corona enhances accuracy of Ca-19.9-based pancreatic cancer classification. Co-author DOI 10.1039/d4nr02435d↗
  2. Novel Biomarkers in Pancreatic Cancer. First author DOI 10.3390/cancers16030628↗
  3. Inflammatory biomarkers and nanotechnology: new insights in pancreatic cancer early detection. Last author DOI 10.1097/js9.0000000000000558↗
  4. Coupling magnetic levitation of graphene oxide–protein complexes with blood levels of glucose for early detection of pancreatic adenocarcinoma Last author DOI 10.1186/s12645-023-00170-1↗
  5. Stratifying Risk for Pancreatic Cancer by Multiplexed Blood Test. Co-author DOI 10.3390/cancers15112983↗
  6. Multiplexed Detection of Pancreatic Cancer by Combining a Nanoparticle-Enabled Blood Test and Plasma Levels of Acute-Phase Proteins. Co-author DOI 10.3390/cancers14194658↗
  7. Nanotechnology Meets Oncology: A Perspective on the Role of the Personalized Nanoparticle-Protein Corona in the Development of Technologies for Pancreatic Canc… Co-author DOI 10.3390/ijms231810591↗
  8. Efficient pancreatic cancer detection through personalized protein corona of gold nanoparticles. Co-author DOI 10.1116/6.0000540↗
  9. Detection of Pancreatic Ductal Adenocarcinoma by Ex Vivo Magnetic Levitation of Plasma Protein-Coated Nanoparticles. Last author DOI 10.3390/cancers13205155↗
  10. Nanotechnology and pancreatic cancer management: State of the art and further perspectives. First author DOI 10.4251/wjgo.v13.i4.231↗
  11. Personalized Graphene Oxide-Protein Corona in the Human Plasma of Pancreatic Cancer Patients. Co-author DOI 10.3389/fbioe.2020.00491↗
  12. Synergistic Analysis of Protein Corona and Haemoglobin Levels Detects Pancreatic Cancer. Co-author DOI 10.3390/cancers13010093↗
  13. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics11010031↗
  14. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study. Co-author DOI 10.1016/j.pan.2018.06.002↗
  15. Personalized liposome-protein corona in the blood of breast, gastric and pancreatic cancer patients. Co-author DOI 10.1016/j.biocel.2015.09.002↗
  16. Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients. Co-author DOI 10.1016/j.colsurfb.2014.10.008↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Damiano D. Caputo · 15 shared papers, 2014–2025 · strength 2.50
  2. Giulio Caracciolo · 15 shared papers, 2014–2025 · strength 2.19
  3. Erica Quagliarini · 9 shared papers, 2020–2025 · strength 1.59
  4. Roberto Coppola · 11 shared papers, 2014–2025 · strength 1.48
  5. Luca Digiacomo · 10 shared papers, 2016–2025 · strength 1.32
  6. Alessandro Coppola · 4 shared papers, 2021–2024 · strength 0.82
  7. Roberto Cammarata · 3 shared papers, 2022–2025 · strength 0.61
  8. Vincenzo La Vaccara · 3 shared papers, 2021–2025 · strength 0.55
  9. Sara Palchetti · 5 shared papers, 2016–2021 · strength 0.50
  10. Heinz Wilfried Amenitsch · 2 shared papers, 2021–2025 · strength 0.36
  11. Riccardo Di Santo · 3 shared papers, 2020–2022 · strength 0.36
  12. Valentina Colapicchioni · 2 shared papers, 2014–2016 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.